Medherant Ltd Appoints New Chair
Medherant Ltd, a University of Warwick spin-out developing a novel transdermal drug delivery patch technology, is pleased to announce the appointment of Dr Ken Cunningham as Chair. Dr Cunningham joins Medherant as the company prepares to move into clinical studies with its leading TEPI Patch® technology.
Ken brings over 25 years of experience in the pharmaceutical industry to Medherant. He is currently Chairman of Abzena as well as Non-Executive Director of Verona Pharma plc. Between 2006 and 2010 Dr Cunningham was at SkyePharma plc, initially as Chief Operating Officer and subsequently as Chief Executive Officer, where he oversaw the late stage development of flutiform® for asthma. Ken holds a Medical Degree from St Mary's, Imperial College London.
Medherant’s first-in-class drug delivery platform, TEPI Patch®, is designed to address many of the failings of previous transdermal drug delivery patches, enabling expansion of the library of drugs available for patch delivery, including those that had previously failed clinical trials due to unsuitability for oral administration. The technology is initially being developed for use with the pain-relief drugs ibuprofen and methyl salicylate, delivering a controlled dose over a period as long as 24 hours. Medherant has raised £2 million in funding to date to advance pre-clinical studies of the TEPI Patch®, in preparation for moving into clinical studies and a series A funding round later in 2017.
Ken Cunningham commented, “I am delighted to join Medherant as Chairman as the team progresses the Company’s TEPI Patch® technology into clinical development. Medherant’s novel transdermal drug delivery patch technology offers significant benefits to patients and the potential to generate value for Medherant’s shareholders. I look forward to contributing to the success of the company.”
Mercia Technologies PLC invested £650,000 as part of a syndicated £1.5 million fundraising round in September 2016. It also contributed early-stage funding to Medherant via its third party funds after the business was spun out from the University of Warwick.
Peter Dines, Head of Life Sciences & Bio-sciences at Mercia, said, “Mercia previously worked with Ken when he chaired Polytherics, which later acquired the Mercia portfolio company Warwick Effect Polymers. He then took the business onto AIM as Abzena plc. We are delighted that he has now taken up this post. Ken has over two decades of experience in this sector and his appointment reflects the enormous potential offered by the TEPI Patch®.”
This article has been republished from materials provided by Medherant. Note: material may have been edited for length and content. For further information, please contact the cited source.
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
Antibody Drug-Conjugate to Target Treatment-Resistant Childhood LeukemiaNews
Researchers have discovered that a protein (5T4) found on the surface of cells contributes to chemotherapy resistance in the most common type of childhood leukaemia. Using a novel approach, early testing shows that targeting the protein with an antibody drug conjugate (ADC) could hold promise in improving treatment.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
Comments | 0 ADD COMMENT
International Conference on Nanomedicine and Nanotechnology
Aug 20 - Aug 21, 2018
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018